BioSpace News Archive

CENTOGENE N.V. and Lifera have announced a strategic collaboration with the formation of a Joint Venture to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council.

Celltrion USA announced the launch of Yuflyma®, a high-concentration and citrate-free formulation of Humira® biosimilar, providing an alternative option for patients.

Zymedi announced the signing of a clinical Cooperative Research and Development Agreement with the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to develop ZMA001 for the treatment of pulmonary arterial hypertension.

IASO Biotechnology and Innovent Biologics, Inc. announced that China National Medical Products Administration has approved the New Drug Application for FUCASO, the world’s first fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.

Sosei Group Corporation announces it has dosed the first subject in a Phase I trial evaluating HTL0048149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.